TTRX Stock Analysis: Buy, Sell, or Hold?
$12.29
-1.04 (-7.84%)
âŧ
5d:
-5.79%
30d:
+22.0%
90d:
+26.52%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When TTRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: TTRX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: TTRX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: TTRX is currently trading at $12.29, which is considered fair relative to its 30-day fair value range of $10.82 to $14.40.
Technical Outlook: Technically, TTRX is in a strong uptrend. The price is currently testing key support at $12.00. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.8% recently.
Market Sentiment: TTRX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.00 (+87.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TTRX is in a strong uptrend. The price is currently testing key support at $12.00. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.8% recently.
Market Sentiment: TTRX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.00 (+87.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$10.82 -
$14.40
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.8%)
- BULLISH: Trading 87.5% below Wall St target ($25.00)
- WARNING: Composite score 35/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.82 -
$14.40
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$12.00
Resistance Level
$15.65
Current Trend
Strong Uptrend
Technical data as of
Oct 5, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-29.62
Wall Street Target
$25.00
(+87.5%)
Share & Embed Analysis
Last updated: October 05, 2026 3:40 PM ET
Data refreshes hourly during market hours. Next update: 4:40 PM
Data refreshes hourly during market hours. Next update: 4:40 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TTRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
23 analysts |
$257 | 48 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$74 | 62 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
20 analysts |
$95 | 54 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 64 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
15 analysts |
$52 | 68 BUY |